Your browser is no longer supported. Please, upgrade your browser.
Settings
AVRO [NASD]
AVROBIO, Inc.
Index- P/E- EPS (ttm)-3.29 Insider Own0.60% Shs Outstand36.44M Perf Week-6.61%
Market Cap447.08M Forward P/E- EPS next Y-3.35 Insider Trans0.83% Shs Float29.56M Perf Month-26.09%
Income-114.20M PEG- EPS next Q-0.88 Inst Own92.09% Short Float10.08% Perf Quarter-21.23%
Sales- P/S- EPS this Y-30.30% Inst Trans14.78% Short Ratio5.85 Perf Half Y-34.25%
Book/sh5.70 P/B1.93 EPS next Y5.10% ROA-47.60% Target Price- Perf Year-41.29%
Cash/sh5.41 P/C2.04 EPS next 5Y- ROE-51.30% 52W Range9.76 - 23.50 Perf YTD-20.95%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.11% Beta-
Dividend %- Quick Ratio9.10 Sales past 5Y- Gross Margin- 52W Low12.91% ATR1.16
Employees123 Current Ratio9.10 Sales Q/Q- Oper. Margin- RSI (14)33.59 Volatility6.88% 8.35%
OptionableYes Debt/Eq0.00 EPS Q/Q-78.30% Profit Margin- Rel Volume2.71 Prev Close11.09
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume509.26K Price11.02
Recom2.00 SMA20-24.34% SMA50-24.29% SMA200-32.31% Volume1,344,120 Change-0.63%
Nov-11-20Initiated Berenberg Buy
Mar-31-20Downgrade H.C. Wainwright Buy → Neutral $13
Jun-27-19Initiated Mizuho Buy $28
Apr-05-19Initiated Janney Buy
Oct-10-18Initiated Guggenheim Buy
Oct-02-18Reiterated H.C. Wainwright Buy $47 → $40
Sep-17-18Initiated H.C. Wainwright Buy $47
Jul-16-18Initiated Wells Fargo Outperform $40
Jul-16-18Initiated Wedbush Outperform $38
Jul-16-18Initiated Morgan Stanley Overweight $37
Feb-25-21 07:00AM  
Feb-08-21 08:07AM  
07:00AM  
Feb-05-21 04:05PM  
Feb-01-21 07:00AM  
Jan-22-21 07:00AM  
Jan-19-21 07:00AM  
Jan-08-21 07:00AM  
Jan-07-21 07:00AM  
Dec-16-20 10:46AM  
Dec-04-20 07:00AM  
Nov-24-20 04:19PM  
Nov-19-20 10:06PM  
04:09PM  
Nov-17-20 07:00AM  
Nov-06-20 07:00AM  
Nov-05-20 07:00AM  
06:18AM  
Oct-29-20 07:00AM  
Oct-26-20 07:00AM  
Oct-21-20 07:00AM  
Oct-06-20 07:00AM  
Oct-05-20 07:00AM  
Sep-29-20 10:48AM  
Sep-28-20 07:00AM  
Sep-25-20 07:00AM  
Sep-04-20 07:00AM  
Sep-03-20 07:00AM  
Aug-12-20 09:41AM  
Aug-07-20 07:00AM  
Aug-06-20 07:00AM  
Aug-05-20 07:00AM  
Jul-27-20 08:23AM  
Jul-08-20 07:00AM  
Jul-06-20 07:00AM  
Jun-29-20 07:00AM  
Jun-24-20 04:16PM  
May-14-20 07:00AM  
May-13-20 07:00AM  
May-09-20 08:36AM  
May-08-20 08:42AM  
May-07-20 07:00AM  
May-06-20 04:05PM  
07:00AM  
May-05-20 07:00AM  
May-04-20 07:00AM  
Apr-14-20 08:58AM  
Apr-12-20 02:26PM  
02:26PM  
Apr-03-20 07:00AM  
Mar-30-20 04:30PM  
02:10PM  
Mar-26-20 07:00AM  
Mar-25-20 07:47PM  
07:00AM  
Mar-19-20 12:00PM  
Mar-17-20 05:58PM  
01:57PM  
12:53PM  
12:25PM  
Mar-16-20 07:00AM  
Mar-09-20 07:00AM  
Mar-05-20 07:00AM  
Feb-24-20 07:00AM  
Feb-18-20 04:01PM  
Feb-12-20 10:08PM  
04:01PM  
Feb-11-20 07:23AM  
Feb-10-20 04:01PM  
Feb-06-20 07:00AM  
Feb-04-20 07:00AM  
Jan-14-20 07:00AM  
Jan-09-20 04:00PM  
Dec-19-19 08:00AM  
Dec-16-19 08:00AM  
Dec-14-19 07:47PM  
Nov-07-19 07:00AM  
Nov-06-19 02:31PM  
Oct-24-19 07:00AM  
Oct-22-19 07:00AM  
Oct-16-19 06:02AM  
Oct-08-19 07:00AM  
Oct-03-19 08:00AM  
Sep-27-19 09:00AM  
Sep-11-19 10:22AM  
Aug-29-19 07:00AM  
Aug-16-19 08:30AM  
Aug-12-19 05:36PM  
Aug-08-19 07:00AM  
04:02AM  
Aug-06-19 08:00AM  
Jul-29-19 08:08AM  
Jul-26-19 07:51AM  
Jul-19-19 04:01PM  
Jul-18-19 05:57AM  
Jul-17-19 04:26PM  
12:35PM  
Jul-16-19 09:58PM  
04:01PM  
Jul-15-19 04:28PM  
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Donenberg Phillip B.DirectorFeb 17Buy11.712,00023,4202,000Feb 18 07:06 PM
MACKAY GEOFFREYPresident & CEODec 24Option Exercise0.41100,00041,320245,123Dec 28 07:46 PM